InsuletRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Insulet (PODD) reported revenue of $762.00M in Q1 2026, with International Omnipod its largest revenue segment at 100%.
InsuletMaker of the Omnipod tubeless insulin patch pump, now indicated for type 2 as well as type 1 diabetes. Omnipod 5 integrates with Dexcom and FreeStyle Libre sensors, so the type 2 franchise sits directly in the path of the GLP-1 driven shift in diabetes treatment mix.
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Insulet (PODD) is a Medical - Devices company. Maker of the Omnipod tubeless insulin patch pump, now indicated for type 2 as well as type 1 diabetes. Omnipod 5 integrates with Dexcom and FreeStyle Libre sensors, so the type 2 franchise sits directly in the path of the GLP-1 driven shift in diabetes treatment mix. It was founded in 2000, is headquartered in Acton, MA and employs about 5,400 people.
As of 2026-Q1, Insulet's revenue breaks down across International Omnipod (100%), Drug Delivery (0%). See the revenue-by-segment chart for the full mix.
Track Insulet's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups Insulet in the GLP-1 sector, alongside Ypsomed (YPSN.SW), DexCom (DXCM) and West Pharmaceutical Services (WST).
If you are researching Insulet, also look at Ypsomed (YPSN.SW), DexCom (DXCM) and West Pharmaceutical Services (WST). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.